Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2000-09-22
2003-02-25
Priebe, Scott D. (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093210, C435S320100, C435S325000, C435S455000, C514S04400A
Reexamination Certificate
active
06524573
ABSTRACT:
BACKGROUND OF THE INVENTION
The control of cell proliferation is a central event in tumorigenesis and often depends on the interactions between growth factors and their specific receptor-activated signaling pathways. The nature of the local extracellular matrix modulates cellular responses to a given signal via various means, for example by affecting the affinity of the ligand for its cognate receptor and by influencing proteolytic processing and internalization (lozzo, R. V. and A. D. Murdoch. 1996
. FASEB J
. 10:598-614).
There is increasing evidence that decorin (Krusius, T. and E. Ruoslahti. 1986
. Proc. Natl. Acad. Sci. USA
83:7683-7687; Day, A. A. et al. 1987
. Biochem. J
. 248:801-805; Fisher, L. W. et al. 1989
. J. Biol. Chem
. 264:4571-4576), a member of an expanding gene family encoding small leucine-rich proteoglycans, plays an role in modulating cell proliferation, cell adhesion, cell migration, and collagen fibril formation. Decorin can bind in vitro to a variety of adhesive and nonadhesive proteins including fibronectin, thrombospondin, various types of collagens, and transforming growth factor-&bgr; (TGF-&bgr;; lozzo, R. V. and A. D. Murdoch. 1996
. FASEB J
. 10:598-614). The binding of decorin to fibrillar collagen carries important biological implications as recently demonstrated by the phenotype of mice lacking the decorin gene (Danielson, K. G. et al. 1997
. J. Cell Biol
. 136:729-743). In these mutant animals, disruption of the decorin gene leads to skin fragility and abnormal collagen morphology, characterized by uncontrolled lateral fusion of fibrils. Binding of decorin to TGF-&bgr; prevents fibrosis of renal glomeruli by neutralizing its biological activity (Border, W. A. et al. 1992
. Nature
360:361-364). Decorin cDNA was recently used as a gene therapy tool for treatment of fibrotic diseases caused by TGF-&bgr; (Isaka, Y. et al. 1996
. Nat. Med
. 2:418-423).
Decorin has also been implicated in the control of cell proliferation. Forced expression of decorin in Chinese hamster ovary (CHO) cells has been demonstrated to lead to decreased growth rate, lowered saturation density, and altered morphology (Yamaguichi, Y. and R. Ruoslahti. 1988
. Nature
336:244-246). It has been suggested that decorin causes these changes in this cell system by sequestering TGF-&bgr;, an autocrine growth stimulator for these cells (Yamaguichi, Y. et al. 1990
. Nature
346:281-284). Decorin is also markedly upregulated during quiescence in human diploid fibroblasts (Coppock, D. L. et al. 1993
. Cell Growth Differ
. 4:483493; Mauviel, A. et al. 1995
. J. Biol. Chem
. 270:11692-11700) and its expression is strongly suppressed upon viral transformation with SV40 (Coppock, D. L. et al. 1993
. Cell Growth Differ
. 4:483-493). Decorin is rarely expressed by malignant epithelial cells from a wide variety of human tumors including colon, pancreas, prostate, and breast carcinomas (lozzo, R. V. and I. Cohen. 1993
. Experientia
49:447-455). However, in the tumor stoma of colon cancer, the amount of decorin proteoglycan is increased markedly through a process that involves hypomethylation of the decorin gene (Adany, R. et al. 1990
. J. Biol. Chem
. 265:11389-11396) as well as induction of this gene product via tumor-secreted cytokines (lozzo, R. V. 1985
. J. Biol. Chem
. 260:7464-7473).
Using a gene transfer approach in human colon carcinoma cells that do not constitutively express this gene, it was demonstrated that de novo expression of decorin reverted the cells to a normal phenotype. In these experiments, the cells lost anchorage-independent growth, failed to generate tumors in scid/scid mice, and became arrested in the G
1
phase of the cell cycle (Santra, M. et al. 1995
. Proc. Nati. Acad. Sci. USA
92:7016-7020). This decorin-induced growth arrest was associated with a marked induction of p21
Waf1/cip1/sdi1
(p21), a potent inhibitor of cyclin-dependent kinase (CDK) activity (Harper, J. W. et al. 1993
. Cell
75:805-816; El-Deiry, W. S. et al. 1993
. Cell
75:817-825). Experiments also have shown that augmented p21 protein is present in a multimeric complex with various cyclins and CDKs in the nuclei of decorin-expressing clones and that its levels can be abolished by abrogating decorin expression (DeLuca, A. et al. 1996
. J. Biol. Chem
. 271:18961-18965).
It has now been found that administration of decorin to tumor cells results in suppression of the growth of tumor cells.
SUMMARY OF THE INVENTION
The present invention provides a method for suppressing tumor growth by administration of decorin, a proteoglycan.
According to one embodiment, a method for suppressing tumor cell growth in an animal comprises administering to an animal suffering from a tumor a decorin gene protein product so that tumor growth is suppressed in the animal. According to one preferred embodiment, the decorin gene product comprises wild-type decorin or &Dgr;decorin. The decorin gene product is administered systemically according to one embodiment, and locally, to the tumor site, in other embodiments.
According to another embodiment, a method for suppressing tumor cell growth in an animal comprises administering to an animal suffering from a tumor a vector expressing a decorin gene protein product so that tumor growth is suppressed in the animal. According to one preferred embodiment, the vector expresses wild-type decorin gene product or &Dgr;decorin. The vector is preferably a retroviral vector or an adenoviral vector.
In one embodiment, the vector is administered to cells of the patient in vivo, either systemically or locally to the tumor site. According to another embodiment, the vector is administered to normal cells of the patient ex vivo to obtain over-expression of the decorin protein gene product by such cells. The cells are then returned to the body of the patient in the vicinity of the tumor.
According to one preferred embodiment, the tumor cells subject to treatment express epidermal growth factor receptors. According to another preferred embodiment, the tumor is characterized by a deleterious p53 mutation.
The animal treated according to the present invention is preferably a human being.
REFERENCES:
patent: 5824655 (1998-10-01), Border
Anderson, Human gene therapy, 1998, Nature, vol. 392, pp. 25-30.*
Gomez-Navarro et al., Gene therapy for cancer, 1999, European Journal of Cancer, vol. 35, pp. 867-885.*
Mastrangelo et al., Gene therapy for human cancer: An essay for clinicians, 1996, Seminars in Oncology, vol. 23, pp. 4-21.*
Rosenberg et al., Gene therapist, heal thyself, 2000, Science, vol. 287, p. 1751.*
Verma, Gene theray: Beyond 2000, 2000, Molecular Therapy, vol. 1, p. 493.*
Varmus, Gene therapy: Not ready for prime time, 1996, Nature Medicine, vol. 2, pp. 7-8.*
Friedmann, Principles for human gene tharapy studies, 2000, Science, vol. 287, pp. 2163-2164.*
Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242.*
Kelloff et al., Cancer chemoprevention: progress and promise, 1999, European Journal of Cancer, vol. 35, pp. 2031-2038.*
Santra et al., An Anti-oncogenic role for decorin, 2000, The Journal of Biological Chemistry, pp. 3515365161.*
Csordas et al., Sustained down-regulation of the epidermal growth factor receptor by decorin, 2000, The Journal of Biological Chemistry, pp. 32879-32887.*
Santra et al., Ectopic Expression of Decorin Protein Core Causes a Generalized Growth Suppression in Neoplastic Cells of Various Hostogenetic Origin and Requires Endogenous p21, an Inhibitor of Cyclin-dependent Kinases, J. Clin. Invest, vol. 100, No. 1, Jul. 1997, pp. 149-157.
Santra et al., De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 7016-7020, Jul. 1995 Biochemistry.
Ständer et al., Decorin gene transfer-mediated suppression of TGF-&bgr; synthesis abrogates experimental malignant glioma growth in vivo, Gene Therapy (1998) 5, pp. 1187-1194.
Moscatello et al., Decorin Suppresses Tumor Cell Growth by Activating the Epidermal Growth Factor Receptor, J. Clin. Invest., vo
Kaushal Sumesh
Priebe Scott D.
Smith Janet B.
Thomas Jefferson University
LandOfFree
Method of suppressing tumor cell growth by administering a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of suppressing tumor cell growth by administering a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of suppressing tumor cell growth by administering a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3142844